Abstract:e15086 Background: Although anti-HER2 tyrosine kinase inhibitors (TKIs) have significantly prolonged survival and improved prognosis in HER2-positive breast cancer patients, resistance is a constant obstacle leading to TKIs treatment failure and tumor progression. Our previous research shows dual inhibition of HER2/CDK12 will prominently benefit the outcomes of patients with HER2-positive breast cancer by sensitizing the tumors to anti-HER2 TKIs treatment. Unfortunately, there is no high selective CDK12 inhibitor in clinical. This study sought to accelerate the CDK12 inhibitor discovery by a deep learning approach. Methods: We developed a large-scale self-supervised graph neural network to learn 11 million unlabelled compounds for molecular representation. And the model was trained with 233,823 kinase domain sequences by drug-target interaction datasets from the BindingDB database. Then, this transformer architecture was used to predict potential CDK12 inhibitors. The candidate hits compounds with diverse skeletons were divided into 50 clusters by clustering analysis. The representative hits with high transform scores and rational binding mode in each cluster were detected in the homogeneous time-resolved fluorescence CDK12 kinase assay. Candidate clusters with half-maximal inhibitory concentrations (IC50) lower than 200 nM were selected into expanded validation and kinase selective panel detection. xCELLigence RTCA system was adopted to monitor cell growth and sensitivity of breast cancer cells to CDK12 inhibitors in a real-time manner. Results: Our predictive transfer learning model yielded satisfactory predictions on various targets including CDK12. We screened a total of 4,527,236 compounds and recommended 50 clusters of potential CDK12 inhibitors for further enzyme activity detection. The IC50 of seven cluster representative compounds is lower than 10 uM. Expanded screening of 500 compounds in these clusters discovered a lot of hits with highly CDK12 selective inhibition. Half of the new compounds are showed promising proliferation inhibition in breast cancer cell lines. Conclusions: Our study provides a highly efficient and end-to-end deep learning approach to discover highly selective CDK12 inhibitors in breast cancer.

Deep learning enables rapid identification of potent DDR1 kinase inhibitors

Generative deep learning enables the discovery of a potent and selective RIPK1 inhibitor

Drug Repositioning via Graph Neural Networks: Identifying Novel JAK2 Inhibitors from FDA-Approved Drugs through Molecular Docking and Biological Validation

Establishment of extensive artificial intelligence models for kinase inhibitor prediction: Identification of novel PDGFRB inhibitors

Discovery of Pyrazolo[3,4- d ]pyridazinone Derivatives as Selective DDR1 Inhibitors via Deep Learning Based Design, Synthesis, and Biological Evaluation

De Novo Structure-Based Drug Design Using Deep Learning

Approach for the Design of Covalent Protein Kinase Inhibitors via Focused Deep Generative Modeling

From pixels to druggable leads: A CADD strategy for the design and synthesis of potent DDR1 inhibitors

Target Identi FI Cation among Known Drugs by Deep Learning from Heterogeneous Networks †

Integration of Genetic Algorithms and Deep Learning for the Generation and Bioactivity Prediction of Novel Tyrosine Kinase Inhibitors

Target identification among known drugs by deep learning from heterogeneous networks

Deep Learning-Driven Discovery of FDA-Approved BCL2 Inhibitors: In Silico Analysis Using a Deep Generative Model NeuralPlexer for Drug Repurposing in Cancer Treatment

Widely Used and Fast De Novo Drug Design by a Protein Sequence-Based Reinforcement Learning Model

De novo generation of multi-target compounds using deep generative chemistry

Advancing Drug Discovery with Deep Learning: Harnessing Reinforcement Learning and One-Shot Learning for Molecular Design in Low-Data Situations

Improving drug discovery with a hybrid deep generative model using reinforcement learning trained on a Bayesian docking approximation

De Novo Generation and Identification of Novel Compounds with Drug Efficacy Based on Machine Learning

Development, validation, and evaluation of a deep learning model to screen cyclin-dependent kinase 12 inhibitors in cancers

Diversity oriented Deep Reinforcement Learning for targeted molecule generation

A deep learning approach to discover cyclin-dependent kinases 12 (CDK12) inhibitors in breast cancer.

Comprehensive assessment of deep generative architectures for de novo drug design